North Carolina Medical Board and North Carolina Board of Pharmacy Protocols for Oral and Transdermal Self-Administered Combined Hormonal and Progestin-Only Contraceptives

Revised 5/20/2025

Pursuant to S.L. 2021-110, these protocols adopted by the North Carolina Medical Board and the North Carolina Board of Pharmacy authorize immunizing pharmacists practicing pharmacy in the state of North Carolina and licensed by the North Carolina Board of Pharmacy to dispense, deliver, or administer the following contraception products as directed below.

Immunizing pharmacists who provide contraception products in accordance with these protocols must also complete North Carolina Hormonal Contraception Training Program

	Contraception	Dispensing Protocol		
Eligible Candidates	 Persons of reproductive age, who voluntarily request contraception, and are at risk of experiencing unintended pregnancy and that the patient is, within reasonable certainty, not pregnant. These protocols may be used for persons < 18 years of age with a parent or legal guardian consent. Persons of reproductive age may be provided any contraceptive allowed by these protocols that is a US Medical Eligibility Criteria (USMEC) category 1 or 2 agent based on completion of a patient assessment and evaluation consistent with current USMEC or the <i>Oral and Transdermal Self-Administered Combined Hormonal and Progestin-Only Contraceptives Patient Questionnaire and Pharmacist-Initiated Hormonal Contraception Assessment and Treatment Care Pathway</i> provided in APPENDIX A for these protocols. An alternative questionnaire, assessment and evaluation may be completed, in a format of the immunizing pharmacists' choosing, as long as it is consistent with current USMEC. A patient questionnaire document may be completed by the patient prior to, or at the time of, the visit and then reviewed with the patient by the pharmacist. Patient has a seated blood pressure (< 140/90 mmHg) measured by a qualified health care provider at the time of assessment. This may be done manually or by a blood pressure machine. If the initial blood pressure reading is 140/90 mmHg or greater, reassess the blood pressure after the patient has been seated for five or more minutes. If blood pressure remains high, then do not dispense, deliver or administer and refer to a medical care provider. Refer to APPENDIX A for guidance regarding eligibility criteria and when a person should start using specific contraceptive methods. 			
Route(s) of	Combined Hormonal Co	ontraceptive (CHCs)		
Administration	Combined Oral Contraceptive (COC)	Transdermal (TD)	Progestin Only Pill (POP)	
Medication	 estradiol valerate/dienogest estetrol/drospirenone ethinyl estradiol/desogestrel ethinyl estradiol/drospirenone ethinyl estradiol/drospirenone/levomefolate ethinyl estradiol/ethynodiol diacetate ethinyl estradiol/levonorgestrel ethinyl estradiol/norethindrone ethinyl estradiol/norgestimate ethinyl estradiol/norgestrel mestranol/norethindrone 	ethinyl estradiol/levonorgestrel ethinyl estradiol/norelgestromin	 drospirenone norethindrone 	
Directions for Use	Take one tablet by mouth daily. Follow guidance for initiation, modification, Contraception Assessment and Treatment Co		Take one tablet by mouth daily.	
Refills	As needed up to a one-year supply. Refills m		upplies, as allowed by the patient's	
Contraindications	 insurance. Patient screening questionnaire must be completed at least annually. Allergy to specific medication or component of medication Blood pressure 140/90 or greater Pregnant or pregnancy suspected Any condition rated in the CDC USMEC Criteria for Contraceptive Use as theoretical or proven risks usually outweigh the advantages (rating = 3) or unacceptable health risk, method not to be used (rating = 4) Patient taking any of the following should be referred to PCP for contraception initiation: Fosamprenivir Phenytoin 			

	Corbonoscopics					
	Carbamazepine Rhough addited.					
	o Phenobarbital					
	o Topiramate					
	Oxcarbazepine					
	o Primidone					
	o Lamotrigine					
	o Rifampin					
	O Rifabutin					
Additional Patient	The dispensing pharmacist shall					
Assessment and	Assess patient's medication history for potential contraindications or drug-drug interactions.					
Education	Assess patient's former and current birth control method, any complications or side effects, and preferred method					
	of birth control.					
	Counsel patient on available birth control methods. If the patient wants a method not available through the					
	pharmacy, refer patient to primary care or women's health provider					
	Assess patient's use of and educate on folic acid supplementation					
	The dispensing pharmacist shall educate every person to whom contraception is dispensed, delivered or administered					
	under these protocols on:					
	How to start the contraceptive method (Quick start method preferred), proper administration and missed dose					
	instructions, safety and efficacy data, routine follow-up for the selected contraceptive method, potential drug					
	interactions, salety and efficacy data, routine follow-up for the selected contraceptive method, potential drug interactions, side effects and who to contact should these occur. FDA-required product information -sheet shall also be					
	provided.					
	 Preventive care, including well-women visits, sexually transmitted infection prevention and screening, Cervical Cancer 					
	screening, and the need to have a regular source of health care/primary care provider.					
	Refer to APPENDIX A , Additional Tools for Pharmacists, for educational materials, sample patient attestation and other					
	pharmacist's resources related to this element					
Notification of	Pharmacists choosing to participate in self-administered contraception dispensing or delivery under the authority of these					
Primary Care Provider						
or Women's Health	protocols shall notify the patient's primary care provider and women's health care provider within 72 hours of initiating					
Care Provider	contraception, if the patient has established relationship with a provider. If the patient does not have a primary care					
Care Provider	provider, the pharmacist shall counsel the patient regarding the benefits of establishing a relationship with a primary care					
	provider, and provide information regarding primary care providers, including private practices, federally qualified health					
	centers, free clinics, or local health departments serving the area in which the patient is located.					
	Refer to APPENDIX A, Benefits to Having a Primary Care Physician and Medical Home, as a resource related to this					
December Determine	element.					
Records Retention:	Records for contraceptives dispensed, delivered or administered pursuant to these protocols shall be maintained in					
	accordance with applicable state and federal law.					

APPENDIX A

US Medical Eligibility Criteria (USMEC) for Contraceptive Use, 2024

USMEC for Contraceptive Use, 2024 (Recommendations and Reports)

https://ncap.memberclicks.net/assets/2024/US-MEC-Full-Article.pdf

USMEC for Contraceptive Use, 2024 (CHART)

https://ncap.memberclicks.net/assets/2024/CDC-Medical-Eligibility-Criteria-2024.pdf

US Selected Practice Recommendations (USSPR) for Contraceptive User, 2024

US SPR for Contraceptive User, 2024 (Recommendations and Reports) https://ncap.memberclicks.net/assets/2024/US-SPR-Full-Article.pdf

Patient Assessment and Treatment Care Pathway

The documents below are in full compliance with the North Carolina Medical Board and the North Carolina Board of Pharmacy's protocol for oral and transdermal self-administered combined hormonal and progestin-only contraceptives. Other assessments, questionnaires, or treatment algorithms may be developed and utilized in any format chosen by the immunizing pharmacist, provided they align with current USMEC recommendations.

Patient Assessment Form

(May be completed by patient in advance and reviewed with pharmacist during the consultation)

Companion Treatment Care Pathway Form

Additional Tools for Pharmacists

Tips for Starting Combined Oral Contraceptives

Quick Start Algorithm

Recommendations for Follow-up After Initiation of Contraception

Management of Missed Doses

Patient Attestation Form

Benefits to Having a Primary Care Physician and Medical Home

Other Resources

North Carolina Association of Pharmacists Hormonal Contraceptive Toolkit

Brith Control Pharmacist

Revised 1/20/2025

Oral and Transdermal Self-Administered Combined Hormonal and Progestin-Only Contraceptives Patient Questionnaire

Patient Name:	Bi	rth Date(mm/dd/yy):	Age:	Visit Date(mm/c	dd/yy):		
Part 1:							
1. Insurance:	Primary Care or Women's Health Provider: Practice Name:					#:	
4.Medication Allergies (List na	me of med	dication(s) and your re	action to them)				
5. Blood Pressure: (Pharmacis	st Use Onl	y)mml	Hg (Reading 1)	mmHg	ı (Reading	g 2)	
If initial BP > 140/90 pharmacis	sts may tal	ke second reading afte	er patient has been se	eated for 5 or n	nore minu	ıtes	
6. Last Menstrual Period (mm/d	d/yy):	7. Height (feet/inches):	8. Weight (pounds):	9. BMI (Pharn	nacist Use Or	nly)	
10. Are you currently taking a	multi-vitan	 nin or folic acid suppl	│ ement?				
□ Diaphragm □Withdrawal 12. Birth Control Method(s) Yo □Condoms □Patch □Ring □Diaphragm □Withdrawal 13. Birth Control History (List you've had with them)	□Ring □Fertility u Would L □Pill □I □Fertility	□Pill □IUD □Implay y Awareness/Natural Fa ike to Discuss and Co IUD □Implant □Dep Awareness/Natural Fa	ant □Depo Provera mily Planning Other: msider at This Visit: po Provera □Spermi mily Planning Other:	cide		lems	
Part 2:							
Screening to Be Reasonably S not pregnant if they have no signs-15-20.					Yes	No	
, , , , ,	14. Do you think you might be pregnant? (Early signs and symptoms of pregnancy include a missed period, tender, swollen breast, nausea with or without vomiting, increased urination, and fatigue)						
15. Did your last menstrual period start within the past 7 days? □Yes □No							
16. Have you abstained from sex since your last menstrual period or delivery? □Yes □No							
17. Have you used a reliable form of birth control consistently and correctly since your last period? □Yes □No							
18. Have you had a miscarriage	or abortion	18. Have you had a miscarriage or abortion in the last 7 days? □Yes □I					

20. Have you given birth within the last 6 months, are you fully or nearly fully breastfeeding, AND have

□Yes

□Yes

□No

 $\square No$

19. Have you given birth in the last 4 weeks?

you had no menstrual period since the delivery?

Part 3:

Medical History		
21. Have you ever been told by a medical professional NOT to take hormones?	□Yes	□No
22. Have you ever received an organ transplant?	□Yes	□No
23. Do you have, or have you ever had malignant liver cancer?	□Yes	□No
24. Do you have, or have you ever had breast cancer?	□Yes	□No
25. Have you had diabetes for more than 20 years? or have you had diabetes with kidney disease	□Yes	□No
(nephropathy), disease of the back of your eye (retinopathy), or nerve damage (neuropathy)?		
26. Have you ever had a heart attack or stroke or been told you had heart disease, including	□Yes	□No
cardiomyopathy, heart failure, atrial fibrillation, and problems with your heart valves?		
27. Do you have any other form of active cancer, including metastatic cancer, for which you are receiving therapy, or you are within 6 months of remission?	□Yes	□No
28. Do you have high blood pressure or hypertension? (Higher than 140/90)	□Yes	□No
29. Do you have, or have you ever had severe liver disease, hepatitis, benign liver tumors, or jaundice		
(yellowing of the skin or eyes)?	□Yes	□No
30. Have you had liver disease with the flow of bile from your liver is blocked or reduced (cholestasis)	□Yes	□No
related to birth control pills?		
31. Do you have, or have you ever had gallbladder disease and still have your gall bladder?	□Yes	□No
32. Do you have ulcerative colitis or Crohn's disease?	□Yes	□No
33. Do you have, or have you ever had a blood clot in your leg (Deep Vein Thrombosis/DVT or	□Yes	□No
Superficial Venous Thrombosis) or lung (Pulmonary Embolism/PE)?		
34. Have you ever been told by a medical professional that you are at risk of developing a blood clot in	□Yes	□No
your leg or lung?		
35. Have you ever been told by a medical professional that you have a blood disorder that increases your risk of developing a blood clot?	□Yes	□No
36. Have you had recent major surgery or are you planning to have major surgery in the next 4 weeks	□Yes	□No
after which you had to or will have to have a long period of time with limited or no movement?		,,
37. Do you have multiple sclerosis with limited or no movement?	□Yes	□No
38. Do you have migraine headaches with aura (warning signs or symptoms such as flashes of light,	□Yes	□No
blind spots, or tingling in your hands or face that comes and goes completely away before the headache		
starts)?		
39. Do you have high cholesterol?	□Yes	□No
40. Do you have 2 or more of the following conditions? Check all that apply to you:		
Age 35 or older	□Yes	□No
Smoke cigarettes or vape nicotine containing products	□Yes	□No
High LDL (bad cholesterol)	□Yes	□No
Low HDL (good cholesterol)	□Yes	□No
High triglycerides (fat in blood)	□Yes	□No
High blood pressure	□Yes	□No
Diabetes	□Yes	□No
41. Has it been less than 21 days since you have given birth or less than 30 days since you have given	□Yes	□No
birth and you are breastfeeding?		
42. Has it been less than 42 days since you have given birth?	□Yes	□No
If yes, do you have ANY risk factors for blood clots? See risk factors below, check all that apply to		

you:		
Age 35 or older	□Yes	□No
Previous blood clot	□Yes	□No
Thrombophilia (blood disorder that makes you more likely to have blood clots)	□Yes	□No
Blood transfusion at delivery	□Yes	□No
Cardiomyopathy around time of giving birth	□Yes	□No
Major bleeding at time of giving birth	□Yes	□No
BMI > 30	□Yes	□No
Pre-eclampsia	□Yes	□No
Smoke cigarettes or vape nicotine containing products	□Yes	□No
Immobility (prolonged periods of limited or no movement)	□Yes	□No
43. Do you have Sickle Cell Anemia?	□Yes	□No
44. Do you have Lupus?	□Yes	□No
45. Have you had Roux-en-Y, gastric bypass, or biliopancreatic surgery?	□Yes	□No
46. Are you on dialysis, or has your doctor ever told you that you have kidney problems such as	□Yes	□No
Nephrotic Syndrome or high potassium?		

Part 4:

Medication History		
47. Are you taking any of the following medications?		
Fosamprenivir	□Yes	□No
Phenytoin	□Yes	□No
Carbamazepine	□Yes	□No
Phenobarbital	□Yes	□No
Topiramate	□Yes	□No
Oxcarbazepine	□Yes	□No
Primidone	□Yes	□No
Lamotrigine	□Yes	□No
Rifampin	□Yes	□No
Rifabutin	□Yes	□No
48. Do you take any other medications for seizures, tuberculosis, or Human Immuno-deficiency Viru	ı s ? □Yes	□No
If yes, list them here:		
•		
		_

Revised 1/20/2025

Pharmacist Initiated Hormonal Contraception Assessment and Treatment Care Pathway

Part 1: Patient Information

1.Review Insurance (Question 1)	of Pocket,		If patient DOES NOT have Insurance and does not want to pay cash, refer to Free reproductive Health Services in the community		
2.Review Patient's PCP (Question 2)	If patient h		If patient DOES NOT have a PCP Counsel on benefits of establishing a PCP and provide		
(Question 2)	Continue	to step 3	information on local providers. Continue to step 3		
3. Record Seated Blood P	3. Record Seated Blood Pressure (Question 5)				
If blood pressure < 140/90 after first (or second) seated reading Continue to step 4			If blood pressure \geq 140/90 upon second seated reading, Refer to PCP or other medical provider		
	Comments:				
For patients who meet elig	For patients who meet eligibility for Combined Hormonal Contraceptives (CHC)s, use routine visits to monitor blood pressure for any changes				
			ents answer YES to question 42 Continue to step 5 gov/health/educational/lose wt/BMI/bmi tbl.htm		
5. Review birth control status & If patient is amenable to product		If patient is amenable to products a pharmacist is able to provide -	If patient desires method outside pharmacists' SO scope - Refer to PCP or other medical provider		

Part 2: Screening to be reasonably sure a patient is not pregnant

	· · · · · · · · · · · · · · · · · · ·			
6. Review que	6. Review questions 14-20			
Question 14	If no - Continue to question 15	If yes	and patient answers NO to question 10 , start 400-800mcg folic acid supplementation and Refer to PCP or women's health provider In addition, if patient has no PCP or women's health provider - Counsel on importance of establishing care and provide information on local providers. See toolkit for list of local providers.	
Questions 15-20	If YES to ANY - Continue to step 7	If NO to	Patient may confirm pregnancy through self-administered pregnancy test, if negative – Pharmacist may choose to continue to step 7 OR Refer to PCP or women's health provider	
Comments:				

Question 14 – Folic acid supplementation may be provided in the form of an OTC daily multi-vitamin (containing 400 mcg folic acid) or an OTC prenatal vitamin supplement (containing 800 mcg folic acid). Of note, OTC prenatal vitamins contain more minerals than standard multi-vitamins and may result in tolerance issues for some individuals.

Questions 15-20 – It is reasonably certain a person is **not pregnant** if they have no signs or symptoms of pregnancy and answer **yes to any** questions **15-20**

Part 3: Medical History

7. Review Questions 21-28	If no to ALL questions, Continue to step 8	If yes to ANY Question Refer to PCP			
8. Review Questions 29 – 44	If no to ALL questions, Continue to step 9	If yes to ANY question	Combined Hormonal Contraception (CHCs) contraindicated		
			Progestin-only Pills (POPs) acceptable - Continue to step 9		
		Comments:			
	Question 40 – For patients who smoke or vape nicotine, ASK patient if interested in smoking cessation counseling Question 42 – Only treat as a YES, if patient < 42 days postpartum AND checks at least one risk factor for blood clots				
9. Review Question 45	If no –	If yes	Oral COCs and POPs Contraindicated		
Continue to Step 10			Transdermal Patch acceptable – Continue to step 10		
10. Review Question 46	If no – Continue to Step 11	If yes	Combined Hormonal Contraceptives (CHCs) Contraindicated		
			In the <u>absence</u> of hyperkalemia -		
			Progestin Only Pills acceptable Continue to Step 11		
			In the presence of hyperkalemia –		
			Norethindrone (POP) acceptable (POP) continue to Step 11		

Comments

Drospirenone (DSRP) POP should not be used in patients with CKD and known hyperkalemia If unsure of a patient's potassium status:

- Pharmacists may choose to offer norethindrone as an acceptable choice if patient is amenable to this product OR
 Pharmacists may choose to confirm patients' potassium status with their PCP or Women's Health Care Provider prior to offering a POP ÓR
- 3. Pharmacists may choose to refer patients to PCP or Women's Health Care Provider for serum potassium check or alternative agent.

Part 4: Medication History

T are in into around in this cory		
11. Review Question 47-48	If no to ALL	If yes to ANY (patient on fosamprenavir, phenytoin, barbiturates,
	complete the "Patient	primidone, topiramate, oxcarbazepine, carbamazepine, rifampin,
	Documentation and	lamotrigine, or rifabutin)
	Communication Form and	Refer to PCP
	dispense preferred	
	medication covered by	
	Statewide Protocol and per	
	treatment care pathway	

Revised 1/20/2025

Tips for Starting Combined Oral Contraceptives (COCs)

- Start with a *monophasic pill* with 20 to 35 mcg of ethinyl estradiol using the quick start method.
 Examples include:
 - a. Sprintec, which contains norgestimate and 35 mcg of ethinyl estradiol (generic form of Ortho-Cyclen)
 - b. If you are looking for a 20-mcg pill, one option is Microgestin 1/20 which contains norethindrone and 20 mcg of ethinyl estradiol (generic form of Loestrin)
 - c. Lowest estrogen option is 10 mcg (Lo Loestrin), some studies have found it is not quite as effective, and more breakthrough bleeding.
- 2. *If the patient prefers a continuous oral contraceptive* to decrease dysmenorrhea and the number of periods or to prevent menstrual migraines.

Examples include:

- a. Jolessa 0.15 mg of levonorgestrel and 30 mcg of estrogen and comes in a 3-month pack (generic form of Seasonale)
- b. Using any monophasic pill but omitting the placebo pills for week 4
- 3. Multiphasic oral contraceptives are designed to mimic fluctuations in hormones during a menstrual cycle. Estrogen/Progestin content varies as the month progresses. There is no significant difference in efficacy between biphasic and triphasic contraceptives, however more bleeding may occur with bi-phasic than tri-phasic.

Examples include:

a. Tri-Sprintec – Day 1-7: 0.035mg estrogen and 0.18mg norgestimate, Day 8-14: 0.035mg estrogen, 0.215mg norgestimate, Day 15-21: 0.035 estrogen, 0.25 norgestimate

4. Special considerations.

Androgenic progestins, highlighted in the table below, may cause acne, hirsutism, oily skin, and increased libido. Clinically not a huge difference. Overall COC's are antiandrogenic.	Androgenic	VTE risk	Breakthrough bleeding
Norethindrone	+		+
Norethindrone acetate	+		+
Norgestrel	++		
Levonorgestrel	++		
Desogestrel		+	
Norgestimate		+	
Drospirenone	-	+	

5. Consideration in switching contraceptives to manage complaints/ adverse effects

Implication	Side Effects with new onset with contraceptive initiation	Considerations for switching contraceptives (to manage complaints/ adverse effects). Consider referral to primary care or women's health provider for evaluation of side effects. Refer to primary care or women's provider if symptoms do not resolve.
Too much estrogen	Nausea, breast tenderness, increased blood pressure	Consider lower dose estrogen formulation, avoid patches which provide the highest estrogen exposure
Too little estrogen	Early or mid-cycle breakthrough bleeding, increased spotting, hypomenorrhea	If bleeding occurs early in cycle, increase estrogen content to 30-35mcg
		If bleeding occurs mid to late cycle, change to triphasic whose progestin dose increases through the cycle (ex.Cyclessa, Tri-Sprintec)
Too much progestin	Breast tenderness, headache, fatigue, changes in mood	Consider switching to a progestin with less progestin activity such as norgestimate (ex. Sprintec), desogestrel (ex. Apri), or drospirenone (ex. Yasmin).
Too little progestin	Late breakthrough bleeding	Change to triphasic whose progestin dose increases through the cycle (ex. Cyclessa, Tri-Sprintec)
Too much androgen	Increased appetite, weight gain, acne, oily skin, increased LDL cholesterol, decreased HDL cholesterol.	Consider switching to a progestin with less progestin activity such as norgestimate (ex. Sprintec), desogestrel (ex. Apri), or drospirenone (ex. Yasmin).

Using the "Quick Start" Method to Initiate Hormonal Contraceptives

Initiation of hormonal contraceptives may be started at any point in the menstrual cycle. Using the (Quick-Start) method has been proven to enhance continuation rates.

The Protocol includes provisions for Pill and Patch only. Ring, Injection, and Implants are excluded.

Quick Start Algorithm for Hormonal Contraception²

Patient requests new birth control method:

Pill, Patch, Ring, Injection, Implant First day of last menstrual period (LMP) is: > 7 days ago. < 7 days ago. Unprotected sex since last LMP? Start method today. A backup method is not needed for injection. If LMP was 5-7 days ago and patient chose pill, patch, ring or implant, a backup method is needed for 7 days Urine pregnancy test: negative Start method today. A backup method Advise patient that early pregnancy is possible, is needed for but hormones would not cause harm.2 7 days. Does the patient want to start a new method now? If the patient had unprotected sex < 5 days ago, offer If the patient had unprotected sex < 5 days ago, Ulipristal or Levonorgestrel emergency contraception offer Levonorgestrel EC today.3 (EC) today.3 Offer prescription, advance supply, or appointment Start method today. for chosen method. Advise patient to use and A backup method is needed for 7 days. alternate method until next menses. Repeat pregnancy test (home or office) in 2-4 weeks.1 Start pill, patch, or ring within 5 days after the start of next period. Return for implant insertion within 5 days after the start of next period. Return for injection within 7 days after the start of next period.

Please Note: While the standard of care and quick-start algorithm include a recommendation for emergency contraception for patients having unprotected sex, North Carolina's protocols do not include provisions for pharmacist dispensing of ulipristal. However, Levonorgestrel EC. (Plan-B One Step®) is available OTC and pharmacists have a clinical responsibility to counsel patients in accordance with best practice.

	Contracep	tive method				
Action	Cu-IUD or LNG- IUD	Implant	DMPA	СНС	POP	
General follow-up						
Advise the patient that they may contact their provider at any time to discuss side effects or other problems or if they want to change the method. Advise patients using IUDs, implants, or DMPA when the IUD or implant needs to be removed or when a reinjection is needed. No routine follow-up visit is required.	X*	X*	X*	X*	X*	
Other routine visits						
Assess the patient's satisfaction with their current method and whether they have any concerns about method use.	X*	X*	X*	X*	X*	
Assess any changes in health status, including medications, that would change the method's appropriateness for safe and effective continued use on the basis of U.S. MEC (i.e., category 3 and 4 conditions and characteristics) (Box 2).	X*	X*	X*	X*	X*	
Consider performing an examination to check for the presence of IUD strings.	X*	t	t	t	t	
Consider assessing weight changes and discussing concerns about any changes in weight and whether changes might be related to use of the contraceptive method.	X*	X*	X*	X*	X*	
Measure blood pressure.	t	t	t	X*	t	


Abbreviations: CHC = combined hormonal contraceptive; Cu-IUD = copper intrauterine device; DMPA = depot medroxyprogesterone acetate; IUD = intrauterine device; LNG-IUD = levonorgestrel intrauterine device; POP = progestin-only pill; U.S. MEC = U.S. Medical Eligibility Criteria for Contraceptive Use.

Appendix D: Routine Follow-Up After Contraceptive Initiation | Contraception | CDC

^{*} The action is applicable to the contraceptive method.

[†] The action is not applicable to the contraceptive method.

Recommended Actions After Late or Missed Combined Oral Contraceptives



Abbreviation: UPA = ulipristal acetate

Source: For full recommendations and updates, see the U.S. Selected Practice Recommendations for Contraceptive Use webpage at http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usspr.htm



Recommended Actions After Delayed Application or Detachment* With Combined Hormonal Patch

Delayed application or detachment for <48 hours since a patch should have been applied or reattached

- Apply a new patch as soon as possible. (If detachment occurred <24 hours since the patch was applied, try to reapply the patch or replace with a new patch.)
- Keep the same patch change day.
- No additional contraceptive protection is needed.
- Emergency contraception is not usually needed but can be considered (with the exception of UPA) if delayed application or detachment occurred earlier in the cycle or in the last week of the previous cycle.

*If detachment takes place but the woman is unsure when detachment occurred, consider the patch to have been detached for ≥48 hours since a patch should have been applied or reattached. Delayed application or detachment for ≥48 hours since a patch should have been applied or reattached

- Apply a new patch as soon as possible.
- Keep the same patch change day.
- Use back-up contraception (e.g., condoms) or avoid sexual intercourse until a patch has been worn for 7 consecutive days.
- If the delayed application or detachment occurred in the third patch week:
- Omit the hormone-free week by finishing the third week of patch use (keeping the same patch change day) and starting a new patch immediately.
- If unable to start a new patch immediately, use back-up contraception (e.g., condoms) or avoid sexual intercourse until a new patch has been worn for 7 consecutive days.
- Emergency contraception should be considered (with the exception of UPA) if the delayed application or detachment occurred within the first week of patch use and unprotected sexual intercourse occurred in the previous 5 days.
- Emergency contraception may also be considered (with the exception of UPA) at other times as appropriate.

Recommended Actions After Delayed Insertion or Reinsertion* With Combined Vaginal Ring

Delayed insertion of a new ring or delayed reinsertion of a current ring for <48 hours since a ring should have been inserted Delayed insertion of a new ring or delayed reinsertion for ≥48 hours since a ring should have been inserted

- Insert ring as soon as possible.
- Keep the ring in until the scheduled ring removal day.
- No additional contraceptive protection is needed.
- Emergency contraception is not usually needed but can be considered (with the exception of UPA) if delayed insertion or reinsertion occurred earlier in the cycle or in the last week of the previous cycle.
- *if removal takes place but the woman is unsure of how long the ring has been removed, consider the ring to have been removed for ≥48 hours since a ring should have been inserted or reinserted.

- Insert ring as soon as possible.
- Keep the ring in until the scheduled ring removal day.
- Use back-up contraception (e.g., condoms) or avoid sexual intercourse until a ring has been worn for 7 consecutive days.
- If the ring removal occurred in the third week of ring use:
- Omit the hormone-free week by finishing the third week of ring use and starting a new ring immediately.
- If unable to start a new ring immediately, use back-up contraception (e.g., condoms) or avoid sexual intercourse until a new ring has been worn for 7 consecutive days.
- Emergency contraception should be considered (with the exception of UPA) if the delayed insertion or reinsertion occurred within the first week of ring use and unprotected sexual intercourse occurred in the previous 5 days.
- Emergency contraception may also be considered (with the exception of UPA) at other times as appropriate.


Abbreviation: UPA = ulipristal acetate

Source: For full recommendations and updates, see the U.S. Selected Practice Recommendations for Contraceptive Use webpage at http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usspr.htm.

CS266008-A



Recommended Actions After Late or Missed Progestin-only Pills



Abbreviations: POP = progestin-only pill; UPA = ulipristal acetate

Source: For full recommendations and updates, see the U.S. Selected Practice Recommendations for Contraceptive Use webpage at https://www.cdc.gov/contraception/hcp/usspr/



Patient Attestation Form

I am requesting that my pharmacist consult with me about my birth control options. I understand the following:

- The pharmacist is providing care based on the information I provide.
- The pharmacist will review my birth control options, if pharmacist is able to provide my selected birth control method, they will review with me how to use it, and what to expect.
- The pharmacist is available to answer all my questions about certain birth control options. I understand pharmacists and physicians have different education and training
- If the pharmacist is unable to provide my desired method of birth control, I will be referred to my primary care or women's health provider.
- Establishing a relationship with a primary care provider or women's health provider is important, so I should request information from the pharmacist about providers in my local area if I do not have one.
- It is advised to have regular visits with a primary care or women's health provider to receive recommended tests and screenings.
- No method of birth control is 100% effective at preventing pregnancy.
- Hormonal birth control does not start working right away to prevent pregnancy. After using hormonal birth control for 7 days, it will prevent pregnancy if used correctly and consistently.
- Hormonal birth control does not protect against sexually transmitted diseases (STDs). Condoms protect against STDs.

I will contact my pharmacist and primary care provider or women's health provider
regarding any side effects, problems, or changes to my health status or medications

Patient Signature	 Date
r atient Signature	Date
Parent or Guardian Signature for persons <18 years of age	 Date



Discover Family Medicine at www.ncafp.com

ALL NORTH CAROLINIANS NEED a Primary Care Physician

Benefits to Having a Primary Care Physician and Medical Home for Your Overall Healthcare

There are many benefits to having your own personal primary care physician and 'medical home' - a place you access all of your healthcare services:

You will be happier and healthier: A primary care physician helps you maintain your optimal health by helping you prevent illness and by expertly managing acute and chronic illnesses, including conditions like the flu, sinus infections, diabetes, high blood pressure, heart disease, depression, and many more. Primary care physicians help you get the right care at the right time!

<u>You will save time and money</u>: Primary care physicians reduce your overall healthcare costs and help you get the right care when you need it most. Patients with a primary care physician miss fewer work days, avoid costly duplicated tests/treatments, and save precious time when health issues do arise.

What is a Family Physician?

A family physician is medically trained to provide comprehensive healthcare to everyone -- male and female -- from birth through old age. Family physicians provide personal healthcare services that are:

- Individualized to you and your specific healthcare needs
- Comprehensive (acute conditions, chronic illnesses, and behavioral health issues)
- · Focused on prevention, which keeps you healthier and happier
- Coordinates your healthcare with sub-specialists, hospitals and others when needs arise
- Relationship-based and lifelong your family physician knows you, your history and your family

To learn more about the importance of having a primary care physician, please visit www.ncafp.com